laparoscopic restorative proctocolectomy
Procedurelaparoscopic restorative proctocolectomy
NCT Number: NCT05495178
Several studies using different methodological approach have revealed incomplete, old and conflicting data on the course of hepatobiliary manifestations after surgery. authors conducted a prospective observational study to evaluate the role of LRP on the course of hepatobiliary manifestations for a better knowledge of these manifestations that is necessary to improve their management.also, to evaluate the role of surgery on prevention of liver damage from progression of the disease.
Looking for future studies?
Notify Me18 year–69 year
All sexes
Observational
Inflammatory bowel disease (IBD) prevalence is expected to reach 1% of the population in many regions over the next decade. despite the fact that the primary clinical manifestations of IBD are centred in the gastrointestinal tract, 25-40% of IBD patients develop at least one extraintestinal manifestation (EIM).
Hepatobiliary manifestations constitute one of the most common EIMs in IBD . Hepatobiliary manifestations are much more commonly associated with ulcerative colitis (UC) and include primary sclerosing cholangitis (PSC), autoimmune hepatitis (AIH), fatty liver, cholelithiasis, primary biliary cholangitis, portal vein thrombosis, and hepatic abscess.
Most UC patients can be managed medically, but a minority requires proctocolectomy. Two-stage laparoscopic proctocolectomy (LPC) with ileal pouch-anal anastomosis (IPAA) is a cure for colitis, but its effect on hepatobiliary diseases is controversial.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
laparoscopic restorative proctocolectomy
Time frame: 4 years
severity of hepatobiliary manifestations are measured by abdominal ultrasonography,liver biopsy ,CT and MRCP
Zagazig University
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05481398
Digestive System Diseases, Hepatobiliary Disease
Karachi, Sindh, Pakistan
View Trial DetailsNCT04213183
Artificial Intelligence, Digestive System Diseases
Guangzhou, Guangdong, China
View Trial DetailsNCT02197481
Digestive System Diseases, Hepatobiliary Disease
Hefei, Anhui, China
View Trial DetailsNCT01918813
Digestive System Diseases, Gastroenteritis
Nishinomiya, Hyōgo, Japan
View Trial Details